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Summary: Neuroﬁ  bromatosis type 1 (NF1) or von Recklinghausen disease is a genetic disorder affecting the growth of 
cells in nervous system. One of the most remarkable characteristics of this disease is the development of benign tumors of 
the nervous system (neuroﬁ  bromas).
The purpose of this study was to test tissue samples taken from neuroﬁ  bromas and plexiform neuroﬁ  bromas of NF1 patients 
for the presence of estrogen and progesterone receptors. We used previously collected samples from patients registered in 
the database of the Centro Nacional de Neuroﬁ  bromatose (CNNF-Brazil). Samples from twenty-ﬁ  ve patients in the database 
presenting plexiform neuroﬁ  bromas (N1 group) and 25 samples from the same database from patients presenting neuroﬁ  -
bromas (N2 group) were tested.
We observed positive staining for progesterone receptors in 13 of the neuroﬁ  broma samples and 19 of the plexiform neuroﬁ  broma 
samples. Among the neuroﬁ  broma samples, we observed one sample with positive estrogen receptor staining, but none of the 
plexiform neuroﬁ  broma samples showed positive staining. We suggest further studies to investigate in greater depth possible 
hormonal inﬂ  uences on the development and growth of neuroﬁ  bromas and plexiform neuroﬁ  bromas in NF1.
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Introduction
Neuroﬁ  bromatosis type 1 (NF1) is an autosomal dominant disorder primarily affecting the cell growth 
of neural tissue. The disorder is caused by a mutation affecting the gene located on chromosome 17q11.2, 
occurs in an estimated 1:3000 births, with considerable variation in clinical presentation and disease 
severity among affected individuals (Gutmann et al. 1997; DeClue et al. 2000; Cunha et al. 2003; Geller 
and Bonalumi Filho, 2004; Geller et al. 2006). The clinical signs and symptoms of NF1 may be present 
at birth or may develop at any age (Theos and Korf, 2006). Common features of NF1 include Lisch 
nodules, café-au-lait spots, freckling in the inguinal and axilary regions and neuroﬁ  bromas (Ferner, 
2007). Multiple neuroﬁ  bromas tend to develop in NF1 patients, but solitary neuroﬁ  bromas may affect 
individuals that do not have NF1 (Geller and Bonalumi Filho, 2004; Theos and Korf, 2006).
One of the most visible signs of NF1 is the dermal neuroﬁ  broma, a benign, heterogenic tumor of the 
nervous system composed of Schwann cells, perineural cells, ﬁ  broblasts, mast cells, and axons in an 
extracellular matrix (De Clue et al. 2000; Zhu et al. 2002; Ferner, 2007). Neuroﬁ  bromas may be focal 
growths or can extend along the length of a nerve and may arise on any part of the body, cutaneously 
or subcutaneously (Theos and Korf, 2006). While cosmetic alterations arising from dermal neuroﬁ  bromas 
are among the chief complaint among NF patients, cutaneous neuroﬁ  bromas may also cause itching 
and stinging, and subcutaneous neuroﬁ  bromas may be painful and cause neurological deﬁ  cit as a result 
of nerve compression (Ferner, 2007).
Plexiform neurofibromas are classified as benign peripheral nerve sheath tumors. They are 
not metastatic, but are highly vascularized and involve multiple nerve fascicles, often making 
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surgical excision difﬁ  cult (Korf, 1999). Plexiform 
neuroﬁ  bromas can occur congenitally, although 
deeper tumors may not be recognized until later in 
life (Geller and Bonalumi Filho, 2004; Theos and 
Korf 2006). Plexiform neuroﬁ  bromas can be very 
large and irregularly shaped, and may cause 
neurological deﬁ  cit due to compression of adjacent 
structures, as well as soft tissue and bony hyper-
trophy (Korf, 1999; Theos and Korf, 2006).
The actions of estrogenic hormones mediated 
through the estrogen receptor (ER) play important 
roles in regulation of growth, differentiation, and 
function of many reproductive organs. Estrogens 
increase proliferation and alter cell properties, in 
part, via induction of growth factor receptor and 
growth factor. In addition ER has an interrelation-
ships with the progesterone receptor (PR) system 
in modulation of responses (Katznellenbongen, 
1996). Progesterone promotes regulation of some 
tissue remodulation and, like other sex steroid 
hormone receptors, is expressed in vascular cells 
(Weigel, 1996).
Some authors suggest an increase in the size and 
number of neuroﬁ  bromas as well as an increased 
potential for malignant transformation of plexiform 
neuroﬁ  bromas during periods of hormonal change, 
specifically puberty and pregnancy (Puls and 
Chandler, 1991; Posma et al. 2003). These 
observations indicate a possible inﬂ  uence of steroid 
hormones on the development of neuroﬁ  bromas 
(Dugoff and Sujansky, 1996; Geller et al. 2006). 
The steroid hormone receptors belong to a large 
group of nuclear ligand-activated transcription 
factors which play a key role in transcriptional 
activation as well as several aspects of biological 
function, including reproduction, metabolism, and 
regulation of development. Hormone binding 
triggers a series of events that result in the activation 
or repression of target genes (Weigel, 1996).
This study was part of the neuroﬁ  bromatosis 
research line subdivided in immunogenetic 
therapeutic investigation supported by reference 
centers in Brazil, together with Harvard Medical 
School
2. The purpose of this study was to observe 
the presence of progesterone and estrogen receptors 
in the neuroﬁ  bromas and plexiform neuroﬁ  bromas 
of male and female patients with NF1.
Materials and Methods
Following Ethical Committee approval (approval 
no.19/04), we performed a descriptive case study 
on 50 NF1 patients registered in the database of 
the Centro Nacional de Neurofibromatose 
(CNNF- Brazil), a national reference center for NF. 
Twenty-ﬁ  ve patients were selected for each group 
among patients in the database presenting plexiform 
neurofibromas (N1 group) and neurofibromas 
(N2 group). The inclusion criteria for this study 
required patients to be diagnosed with NF1 in 
accordance with the diagnostic criteria established 
by revised NIH criteria, be registered in the CNNF 
database, and have stored tumor material from a 
previous biopsy. Patients presenting a clinical 
history of malignant tumors were excluded from 
the study. A careful review of each patient’s 
medical history was performed using information 
stored in the CNNF database.
Serial 5-mµ sections were cut from parafﬁ  n wax 
blocks and collected on silane coated slides. After 
dewaxing, the presence of ER and PR were 
demonstrated by routine immunohistochemistry 
using the LSAB method (LSAB® + KIT, code 
K0690, Dako Corporation, California, U.S.A). 
Antigen retrieval was performed using microwave 
ovens and citrate buffer (pH 6.0) in a pressure 
cooker. Endogenous peroxidase activity was 
eliminated by incubation for 10, 15 and 20 minutes 
in 6% H2O2 in distilled water at room temperature. 
Non-specific protein binding was blocked by 
incubation with a 1:100 dilution of normal goat 
serum in antibody diluent with background 
reducing component (code S3022; Dako 
Corporation, California, U.S.A), for 30 minutes at 
37 
oC. Sections were incubated overnight at 4 
oC 
with a 1:30 dilution of the primary monoclonal 
antibody against ER (clone 1D5; code N1575; 
Dako Corporation, California, U.S.A.) and with a 
1:200 dilution of the primary monoclonal antibody 
against PR (clone 16; code RTU-PGR-312; 
Novocastra
TM, Newcastle Upon Tyne, UK). 
Visualization was performed by incubation for ﬁ  ve 
minutes in diaminobenzidine. Between each step, 
sections were washed three times for 10 minutes 
in Tris buffered saline. All incubations were carried 
out in humidiﬁ  ed chambers to prevent evaporation. 
Sections were counterstained in Mayer’s haema-
toxylin and they were coverslipped with Entellan® 
(code 107961; Merck©, Darmstadt, Germany). 
Negative controls were performed by omission of 
the primary monoclonal antibody. A breast 
carcinoma was used as positive control.
A semiquantitative counting was carried out in 
the region with the highest number of stained cells. 95
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Samples were classified as having “no 
staining” if 5 positive cells were found per 
10 high-power fields, and “positive” if there 
were 5 positive cells/10 high-power fields. 
Fisher’s exact test was used to compare results 
within and between patient groups.
Results
The N1 group (plexiform neuroﬁ  bromas) was 
comprised of 13 male patients and 12 female 
patients, while the N2 group (cutaneous, subcuta-
neous, pendular neuroﬁ  bromas) included 10 male 
patients and 15 female patients. Mean patient age 
in the N1 group was 25 (+10.65), while the mean 
age in the N2 Group was 18 (+13.37).
Table 1 summarizes the results of the analysis. 
We observed positive progesterone receptor stain-
ing in the tumor samples of 13 patients of the N1 
group, of which 7 samples were from male patients 
and 6 were from female patients, with no 
statistically signiﬁ  cant between-gender difference 
in PR staining (p = 1.000) (Fig. 1). In the N2 group, 
we observed positive PR receptor staining in 
19 samples, of which 7 were from male patients 
and 12 from female patients. No statistically 
signiﬁ  cant difference in the number of PR-positive 
samples was observed between the male and 
female patients of this group (p = 0.653). A com-
parison of the number of PR-positive tumor 
samples from both groups did not present statisti-
cally signiﬁ  cant difference (p = 0.139).
Positive ER staining was observed in only one 
sample, from the N2 group, belonging to a female 
patient. This sample did not present positive stain-
ing for progesterone receptor (Fig. 2).
Discussion
We observed positive PR staining from both 
neurofibroma and plexiform neurofibroma 
samples, with no signiﬁ  cant difference based on 
gender within each group or between the two 
groups. Of the 50 tumor samples analyzed, only 
one presented positive ER staining. These 
findings correlate with those presented by 
McLaughlin and Jacks (2003) who found that out 
of 59 neuroﬁ  bromas and plexiform neuroﬁ  bromas 
analyzed for ER and PR, 75% were positive for 
PR while only 5% stained positively for ER. Our 
ﬁ  ndings show 64% (32/50) of the tumor samples 
analyzed with positive PR staining and 2% (1/50) 
positive for ER.
Although their role remains debated, steroid 
hormone receptors have been observed in numer-
ous other human tumor types, including primary 
spinal cord tumors, small-cell lung cancer, and 
solitary pelvic neural tumors, and melanomas (Grill 
et al. 1981; Concolino et al. 1984; Chetkowski 
et al. 1985; Kaiser et al. 1996). In the case of neu-
rofibromas and plexiform neurofibromas, the 
observation of an increase in number, size, and 
malignancy potential—speciﬁ  cally in plexiform 
neuroﬁ  bromas—during puberty and pregnancy 
suggest a hormonal inﬂ  uence in the development, 
growth, and distribution of these tumors. In a 
survey of 59 NF1 patients using hormonal 
contraception, Lammert et al. (2005) found only 
5 patients reporting neuroﬁ  broma growth during 
contraception
20. However, as pointed out by the 
authors, the study was based on a posteriori 
questionnaires. Additional studies to determine the 
presence of neuroﬁ  broma growth in terms of size, 
mass and tumor depth are warranted to conﬁ  rm 
Lammert’s suggestion that hormonal contracep-
tives may not stimulate neuroﬁ  broma growth.
Table 1. Gender distribution of immunopositivity for 
Progesterone Receptor (PR) and Estrogen Receptor 
(ER) by patient group.
N1 Group N2 Group
PR ER PR ER
Male 7/13 0/13 7/10 0/10
Female 6/12 0/12 12/15 1/15
Total 13/25 0/25 19/25 1/25
Figure 1. Plexiform neurofibroma with nuclear staining for 
progesterone receptor. 20x.96
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Fishbein et al. (2007) compared steroid 
hormone receptor expression and ligand-
mediated cell growth in normal human Schwann 
cells with neurofibroma-derived Schwann cells. 
They reported differential expression of ER, PR, 
and androgen receptor in primary neurofibromas 
and neurofibroma-derived Schwann cells, as 
compared to unaffected Schwann cells. How-
ever, expression did not correlate with different 
neurofibroma types, and differences were 
observed between culture samples and primary 
tissue samples. Changes in terms of prolifera-
tion and apoptosis were found to be heteroge-
nous among groups and ligands, and were 
considered to be consistent with increased cell 
accumulation. The authors suggest a direct 
influence of the steroid hormones, through their 
receptors, in the initiation and progression of 
neurofibromas.
The extremely variable clinical expressivity of 
NF1 makes it a challenging disorder for the 
clinician and the researcher. Cutaneous neuroﬁ  -
bromas are among the chief complaint of NF1 
patients for cosmetic reasons, while plexiform 
neurofibromas may present periods of rapid 
growth, causing disﬁ  guration and compression of 
surrounding structures, with severe cases presenting 
as life threatening. To date, treatment remains 
surgical, with complete resection of plexiform 
neurofibromas difficult in many cases due to 
inﬁ  ltration around nerve roots (Korf, 1999). The 
suggestion by Fishbein et al. that future therapy 
may be individualized for each tumor based on its 
steroid hormone characteristics, highlights the 
importance of these and other studies in order to 
gain a greater understanding of the factors contrib-
uting to neuroﬁ  broma growth in a step towards the 
development of alternative treatment for these 
difﬁ  cult tumors.
The results of this study conﬁ  rm the presence 
of progesterone receptors in both neuroﬁ  bromas 
and plexiform neuroﬁ  bromas in patients with 
NF1. The presence of these receptors may 
account, at least in part, for the periods of rapid 
growth and proliferation of neuroﬁ  bromas and 
plexiform neurofibromas observed in many 
NF1 patients, particularly during puberty and 
pregnancy.
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